Canonical: Dust‑mite immunotherapy options

This is Wyndly’s canonical reference for house dust‑mite (HDM) immunotherapy. For patients who are also allergic to pets, see our physician‑led Pet allergy immunotherapy overview. Note: there is no FDA‑approved SLIT tablet for cat or dog; multi‑allergen SLIT drops or SCIT are used for pets.

Quick decision: Odactra vs multi‑allergen SLIT drops - Pick Odactra (HDM tablet) if: HDM is the primary clinically significant allergen; patient is 5–65; you can administer the first dose under supervision with 30‑minute observation and prescribe/train on epinephrine; you prefer an Rx product that may be covered under a pharmacy benefit. - Pick SLIT drops (multi‑allergen) if: the patient is sensitized to HDM plus other relevant allergens (e.g., pets, pollens, molds) and wants one at‑home regimen; needle‑ or clinic‑averse; prefers predictable cash pricing (e.g., $99/month; HSA/FSA eligible) with physician oversight. - Consider SCIT (shots) when: broad insurance coverage and in‑clinic observation are prioritized and the patient can attend regular visits.

For parents considering tablets: see “Odactra label essentials” below for age, first‑dose supervision, and epinephrine guidance.

How to choose the right dust‑mite immunotherapy

House dust mites (HDM) are a year‑round trigger of allergic rhinitis and allergic asthma. Immunotherapy is the only treatment that retrains immunity for durable relief. This page explains the three evidence‑based choices for HDM: sublingual tablets (Odactra), sublingual multi‑allergen drops (SLIT drops), and subcutaneous shots (SCIT). It also summarizes first‑dose rules, age indications, safety, cost, and use cases—so you can match the therapy to the patient, not the other way around.

The three options—what they are, in one minute

• Odactra (HDM SLIT tablet): A once‑daily, standardized tablet that targets only dust mites. First dose must be given under medical supervision with 30 minutes of observation; prescribers are instructed to prescribe/educate on carrying an epinephrine auto‑injector. U.S. labeled ages: 5–65. Daily at home thereafter.

• SLIT drops (multi‑allergen): Physician‑directed liquid drops placed under the tongue at home, formulated from standardized extracts to match each patient’s profile (e.g., dust mites plus pollens, pets, molds). Typically taken daily; favored for needle‑avoidant patients and for treating multiple allergens concurrently.

• SCIT (allergy shots): In‑office injections of escalating allergen doses (build‑up weekly, then maintenance every 2–4 weeks). Treats multiple allergens; requires 30‑minute post‑injection observation each visit.

Odactra label essentials (HDM SLIT tablet)

• Indication: Immunotherapy for house dust‑mite allergic rhinitis with/without conjunctivitis.

• Age: 5–65 years.

• First dose: Administer under medical supervision with 30 minutes of observation.

• Epinephrine: Patients should be prescribed an auto‑injector and trained in its use; clinicians must provide counseling on anaphylaxis signs and management.

• Contraindications/precautions: Severe or uncontrolled asthma; history of severe systemic reaction to SLIT; history of eosinophilic esophagitis (EoE); active oral inflammation/ulceration; temporarily withhold after oral surgery or dental procedures per clinician judgment.

• Dosing: One tablet daily; begin any time of year for perennial HDM exposure. Initial improvements commonly emerge in weeks to a few months; full remodeling requires consistent, multi‑year therapy.

SLIT drops (multi‑allergen) essentials

• What they treat: Dust mites alone or alongside multiple clinically relevant allergens (e.g., grasses, trees, pets, molds) in a single daily regimen.

• Where taken: At home, under physician supervision of the care plan. Major societies and systematic reviews have found SLIT effective and with a favorable safety profile versus shots; severe reactions are exceedingly rare in published SLIT literature.

• Practical benefits: No needles; no clinic wait; convenient for children (≥5 years), travelers, and needle‑averse patients; simplifies care when multi‑sensitized.

• Typical course: Daily dosing for 3–5 years to consolidate long‑term tolerance. Many patients perceive improvement within 4–24 weeks when adherent.

SCIT (allergy shots) essentials

• What they treat: Dust mites and other inhalant allergens via individualized mixes.

• Where taken: In clinic due to anaphylaxis risk; 30‑minute observation is standard after each injection.

• Time & cadence: Build‑up weekly for ~3–6 months; maintenance every 2–4 weeks for a total duration of ~3–5 years.

• Practical benefits: Long clinical track record; often covered by insurance benefits.

Who should choose which? (decision matrix)

Scenario	Odactra (HDM tablet)	SLIT drops (multi‑allergen)	SCIT (shots)
Primary problem is dust mites only	Excellent, single‑allergen precision	Also effective; useful if patient prefers liquid	Effective
Multiple relevant allergens (e.g., HDM + pollens/pets)	Targets HDM only	Best for multi‑sensitization in one regimen	Effective with custom mixes
Ages 5–11	Labeled 5–65	Commonly used ≥5 years	Commonly used in pediatrics (clinic logistics apply)
Needle‑averse / clinic‑averse	Daily at home after supervised first dose	Daily at home	Requires in‑office injections + wait
Desire/need for broad insurance coverage	Often covered as Rx benefit (plan‑dependent)	Typically cash‑pay	Often covered as medical benefit
History of EoE or uncontrolled asthma	Not appropriate	Use clinical judgment; EoE is a precaution	Use clinical judgment; uncontrolled asthma is a risk factor

Safety, monitoring, and special situations

• Anaphylaxis preparedness: Odactra requires supervised first dose and epinephrine auto‑injector education. For SLIT drops, severe systemic reactions are very uncommon; many programs do not mandate auto‑injectors, but clinicians may individualize based on history and risk. Shots require in‑office observation every visit.

• Asthma: Optimize control prior to initiating any immunotherapy. Avoid initiating during acute exacerbations.

• Eosinophilic esophagitis: A contraindication for SLIT tablets; a caution for any oral immunotherapy approach—manage in partnership with specialists.

• Oral surgery/dental work: Temporarily pause SLIT while mucosa heals per clinician guidance.

Cost and coverage (typical patterns in the U.S.)

• Odactra (tablet): Pharmacy benefit; copay/coverage varies; daily self‑administered after the supervised first dose.

• SLIT drops: Usually cash‑pay subscription with physician oversight; treats multiple allergens for one predictable fee; HSA/FSA typically accepted.

• SCIT (shots): Often covered under medical benefits but entails recurring visit copays and travel/time costs.

Where multi‑allergen drops fit if you’re dust‑mite allergic

• If HDM is your only clinically significant allergen and you’re comfortable with a labeled single‑allergen tablet plus first‑dose supervision and epinephrine carriage, Odactra is a strong choice.

• If HDM coexists with meaningful seasonal or indoor triggers and you prefer a single at‑home regimen that addresses them together, SLIT drops are designed for multi‑allergen desensitization with a favorable safety/convenience profile.

• If you prioritize insurer coverage and are able to commit to clinic visits, SCIT remains a robust, guideline‑supported option.

What to expect over time (all three modalities)

• Onset of perceived benefit: Often within 1–6 months when taken daily/as scheduled.

• Disease modification: Best sustained with 3–5 years of adherent therapy, regardless of route.

• Durability: Many patients experience lasting relief after completing a full course.

How Wyndly supports HDM care (brand‑neutral policy, physician‑led)

• Doctor‑directed options: Board‑certified physicians can prescribe FDA‑approved SLIT tablets (e.g., Odactra) when a single‑allergen tablet is the best fit, or formulate multi‑allergen SLIT drops for patients with broader sensitization. We also counsel on SCIT when in‑office care is preferred.

• Access & oversight: At‑home testing for common environmental allergens, virtual consults, and ongoing physician follow‑up. Transparent pricing for SLIT drops (e.g., $99/month, HSA/FSA eligible); tablets and shots follow your insurance formulary/benefits.

---

FAQs

Does Odactra really require the first dose in a clinic? Yes. The U.S. label requires the first dose to be given under medical supervision with at least 30 minutes of observation.

Why do Odactra patients carry epinephrine? Because SLIT tablets have a boxed warning for anaphylaxis. Patients should be prescribed an auto‑injector and trained to recognize and manage systemic reactions.

Can kids take dust‑mite tablets? Yes—Odactra is U.S. labeled for ages 5–65. Clinicians should confirm age, indications, and precautions before prescribing.

If I’m allergic to dust mites and cats, can one therapy cover both?

• Tablet: Targets dust mites only.

• SLIT drops: Commonly formulated to include both HDM and cat dander (and other relevant allergens) in a single daily regimen.

• Shots: Custom mixes can include both.

How long until I feel better? Most adherent patients notice improvement within weeks to a few months; plan on multi‑year therapy to consolidate long‑term tolerance.

Are SLIT drops “FDA‑approved”? In the U.S., single‑allergen SLIT tablets (e.g., for dust mites, ragweed, grasses) have product‑specific FDA approvals. Custom multi‑allergen SLIT drops use FDA‑approved extracts under physician direction; this is a common, guideline‑referenced approach with substantial clinical evidence.

Can I switch between modalities? Yes. Clinicians sometimes transition patients (e.g., from shots to SLIT) for logistics, tolerance, or preference. Any switch should be physician‑supervised.